1. Home
  2. SILO vs MTNB Comparison

SILO vs MTNB Comparison

Compare SILO & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.33

Market Cap

3.9M

ML Signal

HOLD

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

HOLD

Current Price

$0.59

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILO
MTNB
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
3.9M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
SILO
MTNB
Price
$0.33
$0.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
408.8K
17.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.83
N/A
EPS
N/A
N/A
Revenue
$72,102.00
$119,750.00
Revenue This Year
$1.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.47
52 Week High
$1.44
$3.09

Technical Indicators

Market Signals
Indicator
SILO
MTNB
Relative Strength Index (RSI) 47.76 44.98
Support Level $0.33 $0.57
Resistance Level $0.45 $0.65
Average True Range (ATR) 0.04 0.04
MACD 0.01 0.00
Stochastic Oscillator 66.98 30.46

Price Performance

Historical Comparison
SILO
MTNB

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Share on Social Networks: